The first group of volunteers are vaccinated…
[Industry Voice #1] 2020 trends: sponsors,…
Leading mid-size CRO in Russia works through recruitment challenges during the COVID-19 pandemic to complete enrollment on behalf of Handok Inc.
ST. PETERSBURG, RUSSIA, September 23, 2020 /EINPresswire.com/ -- OCT Clinical, a leading Eastern European CRO headquartered in Russia, today announced it has reached target enrollment for a phase III Rheumatology study on behalf of Korean Pharmaceutical company Handok Inc.
The open, comparative, randomized study will test the efficacy and safety of an adhesive bandage for knee osteoarthritis. Handok’s Inc. treatment will be applied every 12 hours and tested against a comparator bandage applied every 24 hours.
OCT’s team met the recruitment goal within 4 months, adhering to all deadlines despite sites on lockdown, remote CRA visits, and other obstacles presented by the COVID-19 pandemic. With an effective risk-management action plan in place, OCT has successfully navigated these circumstances to keep the Sponsor’s timeline on track.
“We are very pleased with the OCT Clinical team for meeting our recruitment goal under such difficult conditions,” said BokJin Hyun, Head of Clinical Research, Handok Inc. “The achievement is quite impressive, considering the challenging circumstances imposed by the global pandemic.”
Within this project, OCT Clinical is responsible for medical writing, regulatory support, project management, medical monitoring, data management, biostatistics, logistics and pharmacovigilance.
“Our team is delighted to be able to demonstrate great performance for Handok Inc.,” said Irina Petrova, Director of Clinical Operations, OCT Clinical. “We welcome the challenge and look forward to further milestones to see to the success of the project.”